Jean-François Pujol
Technik-/Wissenschafts-/F&E-Leiter bei Biocortech SAS
Profil
Jean-François Pujol co-founded Biocortech AS and serves as Chief Scientific Officer.
He is a Professor at the Laennec Medical School.
Previously, he was Head of CNS Department for Roussel Uclaf (now Sanofi-Aventis).
He has been a Member of the Board of Directors at University of Lyon, the Neuroscience Fed Institute, Liège Cyclotron.
Dr. Pujol received an MD and a PhD from the Lyon University.
Aktive Positionen von Jean-François Pujol
| Unternehmen | Position | Beginn |
|---|---|---|
Biocortech SAS
 Biocortech SAS Pharmaceuticals: MajorHealth Technology Biocortech SAS discovers and develops drug therapies for brain disorders. The company is engaged in treating pathologies and focuses its R&D program on depression, schizophrenia and cognitive deficits. Biocortech develops pharmaceuticals for deficient pathways in the adult brain or deficient receptors via the modulation of RNA editing mechanisms. The company was founded by Dinah Weissmann in 2001 and is headquartered in Paris, France. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ehemalige bekannte Positionen von Jean-François Pujol
| Unternehmen | Position | Ende |
|---|---|---|
| University of Lyon | Corporate Officer/Principal | - |
| Roussel Uclaf SA | Corporate Officer/Principal | - |
Ausbildung von Jean-François Pujol
| Ecole Centrale Lyon | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Biocortech SAS
Biocortech SAS Pharmaceuticals: MajorHealth Technology Biocortech SAS discovers and develops drug therapies for brain disorders. The company is engaged in treating pathologies and focuses its R&D program on depression, schizophrenia and cognitive deficits. Biocortech develops pharmaceuticals for deficient pathways in the adult brain or deficient receptors via the modulation of RNA editing mechanisms. The company was founded by Dinah Weissmann in 2001 and is headquartered in Paris, France. | Health Technology |
| Roussel Uclaf SA | Health Technology |
